Cancer drug hope for eye diseases.
DRUGS USED to treat leukaemia could offer a new target for treating the abnormal blood vessels which form in many blinding conditions, such as age-related macular degeneration and diabetic retinopathy.
Researchers from University College London (UCL) found that imatinib, a drug used to treat leukaemia, inhibited angiogenesis--the growth of abnormal blood vessels.
Professor Christina Ruhrberg, of the UCL Institute of Ophthalmology, who led the research, told Medical Xpress: "We discovered an alternative mechanism that regulates blood vessel growth and does not depend on VEGF."
Patients take imatinib orally, offering hope that an anti-angiogenic treatment could be delivered systemically through tablets rather than by anti-VEGF eye injections.
|Printer friendly Cite/link Email Feedback|
|Article Type:||Brief article|
|Date:||Jun 6, 2014|
|Previous Article:||Blood pressure drugs associated with AMD risk.|
|Next Article:||Practice business developers merge.|